Compromise or Capitulation? US Food and Drug Administration Jurisdiction Over Tobacco Products
article has not abstract
Vyšlo v časopise:
Compromise or Capitulation? US Food and Drug Administration Jurisdiction Over Tobacco Products. PLoS Med 6(7): e32767. doi:10.1371/journal.pmed.1000118
Kategorie:
Policy Forum
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000118
Souhrn
article has not abstract
Zdroje
1. YangJS
NovotnyTE
2009 Policy coherence in US tobacco control: Beyond FDA regulation. PLoS Med 6 e1000079 doi:10.1371/journal.pmed.1000079
2. GivelM
GlantzSA
2004 The “global settlement” with the tobacco industry: 6 years later. Am J Public Health 94 218 224
3. FoxBJ
LightwoodJM
GlantzSA
1998 A public health analysis of the proposed resolution of [the 1997 United States] tobacco litigation. Available: http://repositories.cdlib.org/ctcre/tcpmus/US1998. Accessed 25 June 2009
4. WagnerS
1971 Cigarette country; Tobacco in American history and politics New York Praeger
5. BrandtAM
2007 The cigarette century New York Basic Books
6. BorlandR
YongHH
WilsonN
FongGT
HammondD
2009 How reactions to cigarette packet health warnings influence quitting: Findings from the ITC four-country survey. Addiction 104 669 675
7. Campaign for Tobacco-Free Kids 2009 FDA regulation of tobacco products: A common-sense plan to protect kids and save lives. Available: http://www.lungusa.org/atf/cf/%7B7a8d42c2-fcca-4604-8ade-7f5d5e762256%7D/FDA_BILL_SUMMARY.PDF. Accessed 25 June 2009
8. US Department of Health and Human Services 1989 Reducing the health consequences of smoking: 25 years of progress. A Report of the Surgeon General. Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health. DHHS Publication No. (CDC) 89-8411. Available: http://profiles.nlm.nih.gov/NN/B/B/X/S/. Accessed 25 June 2009
9. SiegelM
CarolJ
JordanJ
HobartR
SchoenmarklinS
1997 Preemption in tobacco control: Review of an emerging public health problem. JAMA 278 858 863
10. NovotnyTE
ZhaoF
1999 Consumption and production waste: Another externality of tobacco use. Tob Control 8 75 80
11. BarkerKG
2009 Thank you for regulating: Why Philip Morris's embrace of FDA regulation helps the company but harms the agency. Admin Law Rev 61 197 224
12. McDanielPA
MaloneRE
2005 Understanding Philip Morris's pursuit of US government regulation of tobacco. Tob Control 14 193 200
13. McDanielPA
SmithEA
MaloneRE
2006 Philip Morris's Project Sunrise: Weakening tobacco control by working with it. Tob Control 15 215 223
14. BerlindMH
1998 Design, manufacturing and marketing of tobacco products: Towards a sensible regulatory framework. Philip Morris. Available: http://legacy.library.ucsf.edu/tid/lgs32a00. Accessed 25 June 2009
15. GoldmanL
GlantzS
1994 Evaluation of antismoking advertising campaigns. JAMA 279 772 777
16. FarrellyMC
HealtonCG
DavisKC
MesseriP
HerseyJC
2002 Getting to the truth: Evaluating national tobacco countermarketing campaigns. Am J Public Health 92 901 907
17. FarrellyMC
DavisKC
HavilandML
MesseriP
HealtonCG
2005 Evidence of a dose-response relationship between “truth” antismoking ads and youth smoking prevalence. Am J Public Health 95 425 431
18. FarrellyMC
NonnemakerJ
DavisKC
HussinA
2009 The influence of the national truth campaign on smoking initiation. Am J Prev Med 36 379 384
19. LingPM
NeilandsTB
GlantzSA
2007 The effect of support for action against the tobacco industry on smoking among young adults. Am J Pub Health 97 1449 1456
20. LingPM
NeilandsTB
GlantzSA
2009 Factors associated with young adult smoking behavior: A national survey. Am J Prev Med 36 389 394
21. GiovinoGA
SidneyS
GfroererJC
O'MalleyPM
AllenJA
2004 Epidemiology of menthol cigarette use. Nicotine Tob Res 6 S67 S81
22. GlantzSA
BarnesDE
BeroL
HanauerP
SladeJ
1996 The cigarette papers Berkeley University of California Press 219 224
23. United States District Court for the District of Columbia 2006 United States v. Philip Morris USA, Inc., et al. 449 F.Supp. 2d 1 (D.D.C. 2006). Available: http://library.ucsf.edu/tobacco/litigation/uspm.html. Accessed 25 June 2009
24. BarnesD
BeroLA
1996 Industry-funded research and conflict of interest: An analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law 21 515 542
25. BarnesD
BeroLA
1997 Scientific quality of original research articles on environmental tobacco smoke. Tob Control 6 19 26
26. BarnesD
BeroLA
1998 Why review articles on the health effects of passive smoking reach different conclusions. JAMA 279 1566 1570
27. BarnesD
HanauerP
SladeJ
BeroLA
GlantzS
1995 Environmental tobacco smoke. The Brown and Williamson documents. JAMA 274 248 253
28. BarnoyaJ
GlantzS
2002 Tobacco industry success in preventing regulation of secondhand smoke in Latin America: The “Latin Project”. Tob Control 11 305 314
29. BarnoyaJ
GlantzS
2005 The tobacco industry's worldwide ETS consultants project: European and Asian components. Eur J Public Health 16 69 77
30. BeroL
2003 Implications of the tobacco industry documents for public health policy. Annu Rev Public Health 24 267 288
31. BeroL
2005 Tobacco industry manipulation of research. Public Health Rep 120 200 208
32. BeroL
GalbraithA
RennieD
1994 Sponsored symposia on environmental tobacco smoke. JAMA 271 612 617
33. HirschhornN
BialousS
2001 Secondhand smoke and risk assessment: What was in it for the tobacco industry? Tob Control 10 375 382
34. HongM-K
BeroLA
2002 How the tobacco industry responded to an influential study of the health effects of secondhand smoke. BMJ 325 1413 1416
35. MuggliME
ForsterJ
HurtRD
RepaceJ
2001 The smoke you don't see: Uncovering tobacco industry scientific strategies aimed against environmental tobacco smoke policies. Am J Public Health 91 1419 1423
36. OngE
GlantzS
2001 Constructing “sound science” and “good epidemiology”: Tobacco, lawyers, and public relations firms. Am J Public Health 91 1749 1757
37. SchotlandM
BeroLA
2002 Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Anal 22 131 140
38. United States Court of Appeals 2009 U.S.A. v. Philip Morris, et al. No. 06-5267. Available: http://pacer.cadc.uscourts.gov/docs/common/opinions/200905/06-5267-1181914.pdf. Accessed 25 June 2009
39. World Health Organization 2004 WHO framework convention on tobacco control. Available: http://www.who.int/fctc/en/index.html. Accessed 25 June 2009
40. Framework Convention on Tobacco Control Conference of the Parties 2008 Guidelines for implementation of Article 5.3: Guidelines on the protection of public health policies with respect to tobacco control from commercial and other vested interests. Available: http://www.who.int/fctc/guidelines/article_5_3/en/index.html. Accessed 25 June 2009
41. BlalockJ
BurgardJ
1963 Re: Tobacco Institute, Tobacco Industry Research Committee, and Hill & Knowlton. Brown and Williamson Tobacco Corporation. Available: http://legacy.library.ucsf.edu/tid/akc72d00. Accessed 25 June 2009
42. United States Supreme Court 1995 Rubin v. Coors Brewing Co., 514 U.S. 476. Available: http://caselaw.lp.findlaw.com/cgi-bin/getcase.pl?court=us&vol=514&invol=476. Accessed 25 June 2009
43. SzymanczykM
2009 Letter to Henry Waxman endorsing Family Smoking Prevention and Tobacco Control Act. Available: http://energycommerce.house.gov/Press_111/20090304/hr1256_support.pdf. Accessed 25 June 2009
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2009 Číslo 7
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Význam hydratace při hojení ran
Najčítanejšie v tomto čísle
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- The US Food and Drug Administration Provides a Pathway for Licensing Vaccines for Global Diseases
- Ethics Without Borders